Exvastat Begins Clinical Development Programme for Repurposed Product for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

Exvastat Begins Clinical Development Programme for Repurposed Product for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

NEWS PROVIDED BY

Exvastat Ltd

Nov 21, 2017, 04:00 ET

CAMBRIDGE UK, Nov 16 2017 / / — Exvastat Ltd, a privately held biopharmaceutical company backed by Cambridge Innovation Capital, today announced it has begun a clinical pharmacology trial in healthy volunteers as part of the development programme to evaluate the use of repurposed imatinib for the treatment of Acute Respiratory Distress Syndrome (“ARDS”).

“ARDS is a very serious condition with a high mortality rate for which there are currently no approved therapies, and from which more people die every year than breast or prostate cancer” said David Cavalla, Chief Executive Officer of Exvastat Ltd. “We are using a repurposing strategy backed by strong intellectual property and good preclinical validation, to reformulate an existing drug and fast-track its development for this serious condition.”

“The trial will investigate the pharmacodynamics and safety of imatinib in a human experimental model of ARDS. Imatinib is a well-described drug with a long safety history, that has shown significant promise as a potential treatment for ARDS based on preclinical studies carried out in European and US institutions, as well as clinical case reports of benefit in closely related conditions.” said Dr Charlotte Summers, Chief Scientific Officer of Exvastat Ltd and University Lecturer in Critical Care Medicine at the University of Cambridge.

Ends

Editors notes

About Exvastat Ltd

Exvastat Ltd is a single asset biopharmaceutical company established in 2016 with investment from Cambridge Innovation Capital (CIC). The founders, Drs. David Cavalla, Charlotte Summers and Andrew McElroy, bring extensive experience in drug repurposing, specialist clinical expertise in critical care medicine and a proven track record of success in pharmaceutical product development. The company is working to identify and advance imatinib for the treatment of serious and life-threatening conditions in patient populations with significant areas of unmet need, including ARDS.

For more information, please visit the Exvastat website at http://www.exvastat.com/.

About Cambridge Innovation Capital (CIC)

CIC combines a unique relationship with the University of Cambridge and deep financial and industry links to support rapidly growing intellectual property rich companies in the Cambridge Cluster. The company is committed to building leading businesses from brilliant technologies – with the benefit of some of the most influential figures in the sector and a patient capital structure.